Aims: To evaluate sympathetic system activity in bladder pain syndrome/interstitial cystitis (BPS/IC) patients and to investigate if chronic adrenergic stimulation in intact rats induces BPS/IC-like bladder modifications. Methods: Clinical study-In BPS/IC patients and aged and body mass index matched volunteers TILT test was undertaken and catecholamines were measured in plasma and 24 hr urine samples. Experimental study-Phenylephrine was injected subcutaneously (14 days) to female Wistar rats. Pain behavior, spinal Fos expression, urinary spotting, number of fecal pellets expelled, frequency of reflex bladder contractions, and urothelial height were analyzed. Urothelium permeability was investigated by trypan blue staining. Immunoreactivity against caspase 3 and bax were studied in the urothelium and against alpha-1-adrenoreceptor and TRPV1 in suburothelial nerves. Mast cell number was determined in the suburothelium. In rats with lipopolysaccharide-induced cystitis, urinary catecholamines, and Vesicular Monoamine Transporter 2 (VMAT2) expression in bladder nerves were analyzed. Results: The TILT test showed an increase of sympathetic activity. Noradrenaline levels in blood at resting conditions and in 24-hr urine samples were higher in BPS/ IC patients. Phenylephrine administration increased visceral pain, spinal Fos expression, bladder reflex activity, urinary spotting and the number of expelled fecal pellets. The mucosa showed urothelial thinning and increased immunoreactivity for caspase 3 and bax. Trypan blue staining was only observed in phenylephrine treated animals. Suburothelial nerves co-expressed alpha1 and TRPV1. Mastocytosis was present in the suburothelium. Cystitis increased sympathetic nerve density and urinary noradrenaline levels. Conclusions: Excessive adrenergic stimulation of the bladder may contribute to the pathophysiological mechanisms of BPS/IC. Neurourol. Urodynam. 34:489-496, 2015. 
INTRODUCTION
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic painful condition of the bladder that affects up to 7% of the female population of the western world. 1 Commonly, bladder pain arises at low volumes of bladder filling and may be referred to close areas such as lower abdomen, lower back, vagina, and pelvis, but may also be referred to distant body areas, including the thighs, neck, and head. 2 The pathophysiologic mechanism of BPS/IC is unclear. However, several findings have been observed in the bladder of some of these patients, such as thinner urothelium, with abnormal cell-to-cell adhesion and impaired barrier function. 3 Urothelial cells release an excess of ATP, acetylcholine, nitric oxide, among other neurotransmitters. 3 The suburothelium is also abnormal containing more sensory nerves and inflammatory cells, including mast cells. 4 However, it remains unclear if the urothelial and suburothelial defects correspond to a local problem or are bladder manifestations of a systemic disease. Several facts may support the latter hypothesis. BPS/IC is associated with other somatic and visceral chronic painful conditions including irritable bowel syndrome (IBS), fibromyalgia, Sjogren syndrome, and anxiety disorders. 3 BPS/IC patients often exhibit an exaggerated startle response also seen in patients with IBS or anxiety disorders. 5 The involvement of the sympathetic system in BPS/IC has been little explored. However, it is known that BPS/IC patients excrete high levels of urinary catecholamines 6 and have denser sympathetic innervation. 4 Moreover, there is an increasing body of evidence suggesting that sympathetic system is implicated in chronic painful conditions. Recent studies have demonstrated that irritable bowel syndrome and fibromyalgia course with a state of sympathetic hyperactivity. 7 In complex regional pain syndrome, the pain response to adrenergic stimulation is substantially enhanced and pain can be improved by sympathectomy. 8 A link between chronic pain and the sympathetic system may also be concluded from several animal experiments. Blockade of sympathetic outflow may reduce neuropathic pain following partial sciatic nerve injury. 9 Sympathetic nerve fibers sprout around dorsal root ganglia cells and tangle with cutaneous peptidergic sensory fibers in animal models of neuropathic pain 10, 11 or articular inflammation. 12 Therefore, in this work we aimed to evaluate sympathetic system activity in BPS/IC patients and to verify if a chronic systemic adrenergic stimulation, intended to mimic a state of sympathetic overactivity, induces bladder modifications that mimic those observed in BPS/IC patients.
MATERIALS AND METHODS

Noradrenaline Levels and Autonomic Nervous System Activity in BPS/IC Patients
In 18 BPS/IC patients with active disease (from a cohort previously described elsewhere 13 ), blood and 24 hr urine samples were collected and noradrenaline levels were determined by HPLC (Kit 195-6087, Gilson). Sympathetic activity was investigated with the TILT test in 10 of the 18 patients, who accepted the risks inherent to the test, which include episodes of syncope, dizziness or headache, hypotension, nausea, and changes in heart rate. The increment in sympathetic activity induced by the change in position increases the heart rate, which decreases the interval between P waves and decreases the normal variability of P wave intervals. This physiological event is measured by the variation of the standard deviation of the P wave interval (DSDPP). Two other parameters were also recorded, that investigated the activity of the parasympathetic system. The root-mean-square difference among successive normal R-R intervals measures the variability of the heart period width based on R waves (root mean square successive differences, or rMSSD). The baroreflex sensitivity, a homeostatic mechanism for maintaining blood pressure was assessed as the average of all baroreflex sequences registered as the test progresses (BRS, msec/mmHg). Ten age and body mass index matched healthy volunteers with no lower urinary tract symptoms recruited among the staff members of the Institution were used as controls for noradrenaline measurements and TILT test.
Rat Model of Chronic Adrenergic Stimulation
Since clinical results showed sympathetic hyperactivity and excess of noradrenaline in 24 hr urine samples, the effect of chronic adrenergic stimulation on bladder function was investigated in female Wistar rats (250-275 g, Charles River), na€ ıve or depleted of nociceptive fibers by systemic capsaicin (75 mg/kg, 24 hr before the experiments).
Treatment consisted on the daily subcutaneous injection for 14 days of phenylephrine at doses of 0.5 (PHE0.5) or 2.5 mg/kg (PHE2.5). In preliminary experiments these doses did not cause animal death. In contrast, doses of 5 and 10 mg/kg induced an important mortality rate and were therefore disregarded (data not shown).
Each experiment described below used six animals per group and where performed during light cycle.
Visceral pain behavioral tests, bladder voiding pattern, and colonic activity. Visceral pain behavioral tests were performed in animals after a period of 5 days of habituation to the handler and to the experimental environment. Visceral pain was assessed by performing three different tests. In test 1, adapted from Boucher et al., 14 animal breathing rate, eyes aperture, and body posture using were analyzed. An arbitrary 0-10 scale was used for each parameter. For the breathing rate, every decrease of 10 cycle/min compared with day 1 record was scored 1. For the eye aperture test, the following scale was used: 0 for complete opening, 2 for intermediate opening, 5 for half-closed, 7 for intermediate opening, and 10 for complete closing. For body posture, if animals presented rounded-back with body aligned or motionlessness the score was 10. Otherwise the score was 0. In test 2, adapted from Olivar and Laird, 15 the following parameters were scored: normal 0, piloerection 1, strong piloerection 2, labored breathing 3, licking the abdomen 4, and stretching and contractions of the abdomen 5. In test 3, adapted from Laird et al., 16 referred pain was assessed using Von Frey analysis in the abdomen, using a series of eight Von Frey monofilaments (rated at 4, 6, 8, 10, 15, 26, 60 g). A positive response was recorded when the animal reacted to the filament (abdomen retraction or jump) in three out of the five filament applications. Tests were carried out at baseline and at day 8 and 14 after the onset of PHE treatment.
To characterize voiding pattern the animals after 14 days of PHE2.5 were placed in cages for 1 hr with filter paper covering the bottom. The number of urinary spots was counted. Due to the association between BPS/IC and IBS, the same animals were afterwards placed in another cage with normal bedding to evaluate colonic activity. After 6 hr, the number of faecal pellets expelled per hour was determined.
Cystometries. Bladder reflex activity was analyzed through cystometry under anesthesia (urethane 1.2 g/kg weight, subcutaneously) 14 days after PHE treatment. After bladder exposure saline was infused through the bladder dome (6 ml/hr) and traces obtained for 2 hr after a period of 30 min for stabilization. Animal temperature was maintained at 378C.
Bladder histology. The urinary bladders of saline and PHE2.5 animals were instilled at day 14 with 0.5 ml of 0.5% Trypan blue, under sodium pentobarbital anesthesia (200 mg/kg, intraperitoneal). Animals were immediately decapitated, the bladders were harvested, fixed in 10% buffered formalin, for 24 hr, embedded in paraffin and sectioned at 5 mm. Bladder sections were stained for Hematoxylin-eosin to analyze urothelium morphology and trypan blue staining. Toluidine Blue 0.1% was used to stain mast cell infiltration. Images were acquired and urothelium thickness and bladder mucosa areas were determined using ImageJ 1.43u software.
Immunohistochemistry. At day 14, immediately after cystometry, animals treated with saline, PHE0.5, PHE2.5, and CAP þ PHE2.5 were perfusion-fixed with 4% paraformaldehyde. L6 spinal cord segments were sectioned at 40 mm and immunoreacted against Fos protein. The urinary bladders were further fixed by immersion in 10% buffered formalin, sectioned at 5 mm and immunoreacted against Bax (1:1,000), Caspase 3 (1:500) and cytokeratin 20 (1:200), alpha1 adrenoreceptor (1:500) and TRPV1 (1:500).
Effects of Cystitis on Sympathetic Fibers Density and on Urinary Levels of Noradrenaline
As sympathetic nerve density was shown to increase during chronic inflammation, 12 sympathetic innervation was investigated in rat bladders inflamed with intravesical instillation of 2 mg/kg lipopolysaccharide (LPS) for 1 hr. Saline instillation was used as control. Urine from each animal was collected 24 hr later and pooled for each group to measure urinary noradrenaline by HPLC (Kit 195-6087, Gilson). LPS-and saline-instilled animals were perfused fixed with paraformaldehyde, the bladders sectioned at 50 mm and immunoreacted against vesicle monoamine transporters 2 (VMAT2) 1:1,000. VMAT2 is a membrane protein that transports monoamines, such as noradrenaline, from the neuroplasm into synaptic vesicles, in sympathetic nerve endings.
Statistics
Comparisons between the paired data were performed using paired Student's t-tests. For multiple comparisons, KruskalWallis test followed by Dunn's test was used. P values inferior to 0.05 were considered statistical significant.
RESULTS
Noradrenalin Levels and TILT Test
In 24 hr urine samples, noradrenaline was significantly higher in BPS/IC patients than in controls (102.1 AE 43.7 mg vs. 47.8 AE 17.8 mg, P < 0.05, Table I ). After resting in supine position, plasmatic noradrenaline in BPS/IC patients was higher than in controls (397.0 AE 36.4 pg/ml vs. 204.3 AE 46.4 pg/ml; respectively, P < 0.001, Table I ). At upright position, plasmatic noradrenaline was similar between BPS/IC patients and controls (596.3 AE 30.4 pg/ml vs. 578.3 AE 69.0 pg/ml; P > 0.05, Table I ).
The mean DSDPP of BPS/IC patients was significantly lower than in controls (24.2 AE 18.6 vs. 57.2 AE 23.0, P < 0.05, Table I ). The rMSSD and the BRS were similar in BPS/IC patients and in healthy subjects (5.6 AE 8.4 vs. 6.3 AE 2.8 units and 7.7 AE 8.2 vs. 7.1 AE 3.8 units; P > 0.05, Table I ).
Rat Visceral Pain Behavior
The pain scores in control animals were 0 (Fig. 1A and B) . After 8 days of PHE2.5, test 1 increased to 16 AE 1 and test 2 to 9 AE 0 (P < 0.001 for both tests; Fig. 1A and B) . At day 14, scores were 16 AE 1 and 10 AE 0, for test 1 and 2, respectively (P < 0.001 for both tests; Fig. 1A and B) . Capsaicin pre-treatment blocked the pain behavior induced by PHE2.5 in the two tests (1 AE 0 for test 1 and 3 AE 1 for test 2; P > 0.05, compared to control; Fig. 1A and B).
PHE2.5 decreased the mechanical pain threshold from 54 AE 13 to 10 AE 3 g at day 8, and to 92 g at day 14 (P < 0.001; 
Cystometry and Spinal Fos Expression
During cystometry control animals had 0.43 AE 0.11 contractions/min (Fig. 2A) . After PHE0.5 frequency was 1.12 AE 0.23 contractions/min and after PHE2.5 frequency was 1.47 AE 0.24 contractions/min (P < 0.01 and P < 0.001, respectively; Fig. 2A) . Capsaicin blocked the effect of PHE2.5 (0.38 AE 0.06 contractions/ min; P > 0.05, compared to control; Fig. 2A ). Following cystometry, control animals presented a bilateral Fos expression of 9 AE 6 cells/section at the superficial lamina of L6 spinal cord segment. PHE0.5 and PHE2.5 increased the number of Fos expressing cells/section to 22 AE 6 and to 36 AE 11, respectively (P < 0.001 for both doses; Fig. 2B ). Capsaicin prevented the PHE2.5-induce increase of Fos (8 AE 6/section; P > 0.05, compared to control; Fig. 2B ).
Voiding Pattern and Colonic Activity
The number of urinary spots/hour of control animals were 2.8 AE 1.1. After PHE2.5, it increased to 8.2 AE 3.6 spots/hr (P < 0.05).
In control animals expelled faecal pellets was 0.64 AE 0.36/hr. PHE2.5 increased the number to 1.64 AE 0.29 (P < 0.001).
Urothelial and Suburothelial Morphology
The urothelial thickness of control animals was 40.4 AE 2.4 mm. PHE treatment caused the appearance of large areas of urothelium with a reduced thickness (24.7 AE 2.5 mm for PHE 0.5 rat body weight and 22.4 AE 1.5 mm, for PHE2.5, P < 0.001 for both doses). Thin urothelium in PHE2.5 treated rats showed increased trypan blue staining indicating an increase in urothelium permeability (Fig. 3A) . Cytokeratin 20 stained the urothelium of control animals (Fig. 3B) but disappeared from large urothelial areas after PHE2.5 (Fig. 3C) . A robust caspase and bax staining could be seen in large urothelium areas of PHE2.5 animals ( Fig. 3D and E) .
In PHE2.5 bladders, sub-urothelium contained 21.3 AE 10.2 mast cells/mm 2 while control animals had 8.2 AE 4.0 mast cells/ mm 2 (P < 0.01). In the sub-urothelium of control animals, alpha 1-adrenoreceptor and TRPV1 immunoreactivity co-localized in nerve fibers (Fig. 3F) .
Effects of Cystitis on Sympathetic Fibers Density and on Urinary Levels of Noradrenaline
Sympathetic fibers were statistically significant denser in the body and dome of muscular and suburothelial layers of lipopolysaccharide (LPS)-inflamed bladders than in control animals (P < 0.05, comparing sham suburothelium dome with LPS suburothelium dome, P < 0.01 comparing sham suburothelium body with LPS suburothelium body, and sham muscular dome with LPS muscular dome, P < 0.001 comparing sham muscular body with LPS muscular body; Fig. 4 ). No differences were observed in the trigone (Fig. 4) .
LPS treatment induce a massive increase in urinary levels of noradrenaline (2341.2 mg) when compared to control animals (<3 mg).
DISCUSSION
This study found sympathetic nervous system overactivity in BPS/IC patients, as demonstrated by the decreased variability between P wave intervals, assessed by the DSDPP during the TILT test. This finding was consistent with the higher urinary noradrenaline levels in patients than the aged-matched healthy individuals, a finding that confirms a previous report. 6 The expected subsequent adrenergic overactivity is in line with the higher mean blood pressure and elevated heart rate during bladder hydrodistention reported by others in BPS/IC patients. 17 Also this agrees with an increased sympathetic innervation of BPS/IC bladders. 4 To establish a causal relationship between an adrenergic overactivity and the bladder changes occurring in BPS/IC, we induced in na€ ıve rats a prolonged stimulation with PHE, a potent non-catecholamine predominantly alpha adrenoreceptor agonist. This drug was chosen due to the fact that urothelial cells express alpha1 adrenoreceptors. 18 Adrenergic stimulation with PHE reproduced in many aspects the clinical picture of BPS/IC. PHE increased the score of pain behavior tests used for visceral pain and enhanced spinal Fos expression after innocuous filling (cystometry). PHE also increased urinary spotting and the frequency of bladder reflex contractions. Hence, our data suggests that in rats under adrenergic stimulation, voiding occurs at lower volumes and is accompanied by an intense barrage of nociceptive input, which may be considered equivalent to frequency and pain reported by BPS/IC patients during bladder filling. PHE treatment also induced histological changes in the bladder that resemble the typical pathologic findings observed in BPS/IC patients. PHE induced extensive urothelial thinning essential due to a loss of cytokeratin 20-positive umbrella cells and increased urothelial cell permeability to trypan blue. The mast cells number in the rat suburothelial layer was increased. In addition, PHE activated pro-apoptotic proteins like Bax and active caspase 3 in the superficial layers of the urothelium, which is similar as a finding recently described in BPS/IC patients. 19 The stimulation of alpha adrenoreceptors in these cells might explain these apoptotic changes. In fact, overstimulation of the adrenoreceptors induces apoptosis through activation of oxidative stress pathways. 20 We observed the co-localization of alpha1 adrenoreceptors and TRPV1 in bladder nerves. TRPV1 is essential for pain and bladder hyperactivity during cystitis and is overexpressed in the suburothelial nerves of BPS/IC patients. 21 Such co-localization explains why capsaicin, a desensitizing agent of TRPV1, totally abolished the PHE-induced increase of bladder reflex activity and Fos overexpression in the spinal cord. However, more relevant, elucidation of the pathways linking alpha1 adrenoreceptors and TRPV1 in nociceptive fibers may be rewarding to understand the role of the sympathetic system in other forms of chronic pain.
Pan cystitis is a pathological finding that could be found in bladder samples of some BPS/IC patients. The origin of inflammation is yet unclear although urothelial changes have been suggested to increase the permeability of the urothelium to urine content. 22 Our data, suggests that chronic cystitis may also have an adrenergic contribution. Mast cell migration and degranulation are enhanced by adrenergic stimulation, which might involve the stimulation of alpha adrenoreceptor expressed by these cells. 23 The sympathetic nervous system was also shown to regulate human immune system function through noradrenaline activation of alpha1 adrenoreceptors expressed by immunocompetent cell such as lymphocytes. 24 An increased density of sub-urothelial nerve fibers seems to be a rule in chronic cystitis. In previous studies sensory fibers had been shown to increase in the suburothelium of inflamed bladders. 25 The present study has also shown an increased density of sympathetic nerves in the suburothelium and muscular layer of the inflamed bladders. This is in line with the recent report of an increased sympathetic innervation in chronic inflamed rat joints. 12 Interestingly, sympathetic sprouts were described very close to sensory fibers. 11 Thus, noradrenaline release from sympathetic nerve endings may have a paracrine influence on sensory fibers which, as seen before, express adrenoreceptors. As the rat urinary noradrenaline levels were markedly increased during cystitis, such paracrine effect might be quite intense.
BPS/IC is often associated with other painful syndromes, such as fibromyalgia and IBS, 5 a fact that itself indicate a systemic mechanism common for all of them. In IBS increased levels of urinary noradrenaline 26 and an altered noradrenergic activity have also been reported. 27 In the present work, chronic adrenergic stimulation in rats mimics those associations. PHE treatment increased somatic pain and colon motility, as seen by the mechanical hyperalgesia in the abdomen and increased number of expelled faecal pellets. Therefore, these findings should be considered as a further reinforcement of the relevance of the sympathetic system as a pathophysiological mechanism of BPS/IC and associated pathologies.
Our study has several limitations. The number of patients and healthy volunteers that performed the TILT test was low, as already mention in material and methods. The origin of the sympathetic dysfunction was not revealed. However, a recent study suggested that non-bladder pelvic surgeries might be related with the onset of BPS/IC, 28 indicating that surgeries or other unrecognized pelvic insults may trigger the sympathetic dysfunction. Also, this study does not elucidate the adrenoreceptor subtypes that may be implicated in the bladder changes induced by adrenergic stimulation. Noradrenaline might stimulate both alpha and beta adrenoreceptors, while PHE, although acting preferentially on alpha adrenoreceptors, might also induce beta-adrenergic mediated effects. 29 Concerning beta adrenoreceptors, human bladder express the beta3 subtype. 30 When stimulated, this adrenoreceptor decreases detrusor contractility and urinary frequency. Mirabegron, which is the first beta3 agonist to be clinically approved for the treatment of bladder overactivity, does not cause bladder pain or any change in bladder morphology. 31 Concerning alpha adrenoreceptors, only 1A and 1D are highly expressed in the urinary bladder urothelium. 32 Thus, this study warrants further research to explore the therapeutic role of alpha1A and D adrenoreceptors antagonists in chronic bladder pain.
In conclusion, the present clinical and experimental observations suggest that sympathetic overactivity is implicated in the mechanism leading to BPS/IC, which opens new opportunities in BPS/IC research.
